IP Library Granted Patent US 8,735,135
Granted Patent B2
US 8,735,135 · App. 12/449,868 · Granted May 27, 2014

Transformed strains originated from multidrug efflux protein defective strains and a method for microbial conversion using them

Inventors: Tadashi Fujii (Tokyo, JP); Atsushi Ochiai (Tokyo, JP); Masashi Ito (Tokyo, JP); Hiroki Kabumoto (Tokyo, JP); Yoshikazu Fujii (Tokyo, JP); Kazuhiro Machida (Tokyo, JP)
Assignee: Microbiopharm Japan Co., Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,735,135
App. No.
12/449,868
Granted
May 27, 2014
Kind
B2
Abstract

Disclosed is a means for improving the poor conversion efficiency in a conventional bioconversion system using a transformant which is given by introducing a gene originated from xerogenic organisms. A transformant is prepared by using a host which is defective in a gene encoding a multidrug efflux protein and introducing a gene originated from xerogenic organisms. Use of the transformant results in much effective microbial conversion of a hydrophobic or amphipathic substrate compound into a desired compound. In case, an Escherichia coli is used as the host, the gene encoding a multidrug efflux protein to be defective may be tolC, acrA, acrB and the like.

Claims (4)

1. A transformant obtainable by the process comprising introducing (a) a gene originated from a xenogeneic organism encoding an enzyme selected from the group consisting of cytochrome P-450 enzyme categorized into family CYP105 and cytochrome P-450 enzyme categorized into family CYP107 into (b) E. coli defective in a gene encoding multi drug efflux protein and selected from the group consisting of tolC and acrAB.

2. A method of microbial conversion which uses the transformant according to claim 1 .

3. A method of microbial conversion according to claim 2 , characterized by performing monooxygenation to a substrate compound.

4. The method according to claim 3 , wherein the substrate compound is selected from the group consisting of vitamin D 3 , 4-cholesten-3-one, and compactin.

Assignments (6)
CHANGE OF ADDRESS Recorded Mar 4, 2022
From: MICROBIOPHARM JAPAN CO., LTD.
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 059792/0794 →
CHANGE OF NAME AND ADDRESS Recorded Mar 4, 2022
From: MICROBIOPHARM JAPAN CO., LTD.
To: SANLI HOLDINGS CO., LTD.
Reel/Frame 059793/0517 →
SPLIT & SUCCESSION Recorded Mar 4, 2022
From: SANLI HOLDINGS CO., LTD.
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 059318/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2012
From: MERCIAN CORPORATION
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 027499/0035 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2011
From: DODDS, JACK
To: GEO EQUIPMENT MANUFACTURING LIMITED
Reel/Frame 026062/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2010
From: FUJII, TADASHI; OCHIAI, ATSUSHI; ITO, MASASHI; KABUMOTO, HIROKI; FUJII, YOSHIKAZU; MACHIDA, KAZUHIRO
To: MERCIAN CORPORATION
Reel/Frame 023760/0680 →
Priority Claims (1)
JP 2007-050935 · Mar 1, 2007 · national
Continuity (1)
Related Publication 20120040441A1 · Feb 16, 2012